Compare Mesoblast Limited (MESO) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs RLX Technology Inc — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while RLX Technology Inc trades at $1.73 (market cap $2.10B). The key difference: RLX Technology Inc is the larger of the two by market cap, and RLX Technology Inc pays a 5.81% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and RLX Technology Inc for 35 Days on average.
| MESO | RLX | |
|---|---|---|
Market Cap | $1.75B | $2.10B |
Volume | 239,027 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $20.96 | $2.57 |
52-Week Low | $13.19 | $1.68 |
Typical Hold Time | 15 Days | 35 Days |
Enterprise Value | $1.83B | $832.26M |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
RLX trades at $1.73, unchanged on the day, and has recently set new 52-week lows. The technical outlook is bearish, with moving averages signaling selling pressure. Fundamentally, the company reported $3.62B in 2025 revenue and $921.87M net income, though recent quarters show earnings misses against expectations. International expansion, now 70% of revenue, drives growth, but margin compression is a concern. Analyst coverage is limited, with a single hold rating indicating caution.
The outlook is mixed; strong international growth and a discounted valuation (P/E 15.46, P/B 0.91) offer potential upside, but persistent earnings misses, bearish technicals, and regulatory risks in the e-vapor industry pose significant headwinds. Investor sentiment remains neutral to cautious amid recent price weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
